Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide

K. A. Van Nifterik, J. Van Den Berg, W. F. Van Der Meide, N. Ameziane, L. E. Wedekind, R. D.M. Steenbergen, S. Leenstra, M. V.M. Lafleur, B. J. Slotman, L. J.A. Stalpers, P. Sminia

Research output: Contribution to journalArticleAcademicpeer-review

90 Citations (Scopus)


Background:The DNA repair protein O 6-methylguanine-DNA methyltransferase (MGMT) can cause resistance to the alkylating drug temozolomide (TMZ). The purpose of this study was to determine the relationship between the MGMT status, determined by means of several techniques and methods, and the cytotoxic response to TMZ in 11 glioblastoma multiforme (GBM) cell lines and 5 human tumour cell lines of other origins.Methods:Cell survival was analysed by clonogenic assay. The MGMT protein levels were assessed by western blot analysis. The MGMT promoter methylation levels were determined using methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) and quantitative real-time methylation-specific PCR (qMSP). On the basis of the results of these techniques, six GBM cell lines were selected and subjected to bisulphite sequencing.Results:The MGMT protein was detected in all TMZ-resistant cell lines, whereas no MGMT protein could be detected in cell lines that were TMZ sensitive. The MS-MLPA results were able to predict TMZ sensitivity in 9 out of 16 cell lines (56%). The qMSP results matched well with TMZ sensitivity in 11 out of 12 (92%) glioma cell lines. In addition, methylation as detected by bisulphite sequencing seemed to be predictive of TMZ sensitivity in all six cell lines analysed (100%).Conclusion:The MGMT protein expression more than MGMT promoter methylation status predicts the response to TMZ in human tumour cell lines.

Original languageEnglish
Pages (from-to)29-35
Number of pages7
JournalBritish Journal of Cancer
Issue number1
Publication statusPublished - 29 Jun 2010

Bibliographical note

Funding Information:
Temozolomide was a generous gift from Schering-Plough RS. This work was supported by the Dutch Cancer Society Grant No. VU 2000-2149.


Dive into the research topics of 'Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide'. Together they form a unique fingerprint.

Cite this